Spruce Biosciences Inc is a biopharmaceutical firm dedicated to creating innovative treatments for rare endocrine disorders. Its flagship project, tildacerfont, is a groundbreaking non-steroidal therapy currently in advanced clinical trials. This therapy aims to improve disease management and lessen the reliance on steroids for patients with congenital adrenal hyperplasia (CAH). Additionally, Spruce Biosciences is exploring tildacerfont's potential in treating polycystic ovary syndrome. Founded in 2014 and based in South San Francisco, California, the company collaborates with industry leaders like Eli Lilly and Kaken Pharmaceutical to bring its therapies to a global market.
Pre-Market Stock Futures: Futures are trading modestly higher after a stunning opening to the week, as all major indices rocketed higher. The announcement of a cease-fire deal with Iran, which the…
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
